Samura Fund Increases Stake in ALUMIS by $10 Million, Expanding Ownership to 5.4%

On January 9, according to a U.S. Securities and Exchange Commission filing, Samura Opportunity Fund L.P.—reported by insider Srinivas Akaraju—increased its stake in Alumis Inc. (NASDAQ: ALMS) by purchasing 588,235 shares of common stock on the open market and in a follow-on offering at roughly $17 per share, for a total outlay of about $10 million. After this trade, the fund’s indirect holdings rose to 1,853,488 shares. Together with the 4,491,731 shares held by affiliated entity Samura BioCapital L.P., Akaraju and his affiliates now own 6,345,219 shares, representing approximately 5.4% of Alumis’s outstanding stock. In the amended Schedule 13D filing, they stated that the share increase is for investment purposes only and did not disclose any activist plans such as board representation or strategic demands.

Alumis, headquartered in South San Francisco, is a clinical-stage biotech company developing next-generation, orally delivered targeted therapies for immune-mediated diseases using a precision data-analytics platform. Its lead asset, enebuticitinib (formerly ESK-001), is a selective, oral TYK2 inhibitor currently in late-stage trials for moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The company’s pipeline also includes A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory and degenerative disorders, and ronigutamab, a candidate for thyroid eye disease. In 2025, Alumis merged with Acelyrin to bolster its cash reserves and expand its late-stage clinical portfolio.

Following positive topline results from the Phase 3 plaque psoriasis study of enebuticitinib, Alumis on January 7 upsized a planned public offering to approximately $300 million at $17 per share. By January 9, including the full exercise of the underwriters’ option, the company issued 20,297,500 shares and raised a total of $345.1 million. Alumis’s stock has exhibited heightened volatility—up over 95% in early January and reaching an intraday high of $22.33 on January 13. Industry analysts believe that, given enebuticitinib’s competitive efficacy versus Johnson & Johnson/Protagonist’s IL-23 inhibitors and Takeda’s TYK2 inhibitor, institutional interest will continue through the anticipated FDA submission in the second half of 2026.